By Connor Hart
Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder cancer in the European Union.
The stock rose 4.6%, to $2.29, in premarket trading Friday. Through Thursday's close, shares have lost about 30% of their value over the past year.
The biotechnology company said the recommendation is based on a review of a recent clinical trial, in which signs of cancer disappeared for more than 70% of patients receiving the treatment, called Anktiva.
The recommendation will help facilitate early access to medicines that address conditions where the remaining treatment option is surgery to remove the bladder, ImmunityBio said.
"Hundreds of patients in the U.S. are already experiencing the benefits of this therapy, and our goal is to make it available to patients in Europe and other parts of the world as quickly and responsibly as possible," said Patrick Soon-Shiong, ImmunityBio's global chief scientific and medical officer.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 12, 2025 06:47 ET (11:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.